CASE STUDY PRA Leads Novel Multiple Myeloma Drug Development Program Expanded Access Program Follows Accelerated ApprovalPRA Leads Novel Multiple Myeloma Drug Development Program Expanded Access Program Follows Accelerated Approval PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client, which enrolled more than 1,100 patients globally at a rate of approximately 0.3 patients/site/ month. The Phase III study included 50 sites, and with the addition of the “rollover study,” grew to 105 sites. PRA assisted the client with the design of the trial and quickly assigned resources to the project for rapid study start-up. At its peak, the trials employed 58 PRA clinical team members and 32 additional data and safety team me

Join for free to read